

REMARKS

Claims 1-10, 21-22 and 32-33 are pending in the instant application. Claims 8-10, 21-22 and 32-33 are rejected. Claims 1-7 are objected to. Claims 1-6 have been amended. Claims 8-10, 21-22 and 32-33 have been cancelled. After entry of this amendment, Claims 1-7 will remain pending.

Rejection of Claims 8-10, 21-22 and 32-33 under 35 USC §112, first paragraph

The Examiner has rejected Claims 8-10, 21-22 and 32-33 under 35 U.S.C §112, first paragraph for allegedly failing to comply with the enablement requirement. Specifically, the Examiner contends that motor proteins were not understood well enough to apply the inhibition thereof to the clinical application of that activity.

Without conceding the correctness of the Examiner's objection, but to advance the prosecution of the instant application, Applicants have cancelled Claims 8-10, 21-22 and 32-33.

In light of these cancellations, Applicants respectfully request the rejection of Claims 8-10, 21-22 and 32-33 under 35 U.S.C. §112, first paragraph, be withdrawn.

Objection to Claims 1-7

The Examiner has objected to Claims 1-7 as containing nonelected subject matter. Applicants have amended Claims 1-7 to limit their scope to that of Group I. In light of these amendments, Applicants respectfully request the objection of Claims 1-7 be withdrawn.

If a telephonic communication with the Applicants' representative will advance the prosecution of the instant application, please telephone the representative indicated below. Applicants believe no additional fees are due but the Commissioner is authorized to charge any fees required in connection with this response to Merck Deposit Account No. 13-2755.

Respectfully submitted,

By



Nicole M. Beeler

Reg. No. 45,194

Attorney for Applicants

MERCK & CO., INC.

P.O. Box 2000

Rahway, New Jersey 07065-0907

(732) 594-1077

Date: April 21, 2008